News
PCVX
60.30
-0.95%
-0.58
Weekly Report: what happened at PCVX last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at PCVX last week (0408-0412)?
Weekly Report · 04/15 09:20
Vaccine Player Vaxcyte Has Advantage Over Pfizer, Merck's Pneumococcal Shots - Analyst Says
Vaxcyte Inc estimates pneumococcal conjugate vaccines market will grow to $12 billion in the next few years. The market is currently split into 25% adults and 75% infants. Needham maintains the Buy rating with a price target of $95 for the company.
Benzinga · 04/10 18:42
Vaxcyte Price Target Maintained With a $95.00/Share by Needham
Dow Jones · 04/10 11:29
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 04/10 10:50
Weekly Report: what happened at PCVX last week (0401-0405)?
Weekly Report · 04/08 09:21
Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst
Needham analyst says Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma. The three companies are the most likely to be acquired in Needham's coverage universe. Needham expects M&A activity to remain above average for the remainder of 2024.
Seeking Alpha · 04/07 12:00
Weekly Report: what happened at PCVX last week (0325-0329)?
Weekly Report · 04/01 09:21
Weekly Report: what happened at PCVX last week (0318-0322)?
Weekly Report · 03/25 09:21
Weekly Report: what happened at PCVX last week (0311-0315)?
Weekly Report · 03/18 09:21
Oracle To Rally Around 40%? Here Are 10 Top Analyst Forecasts For Tuesday
Oppenheimer cut the price target for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) on Monday. Morgan Stanley cut the prices target for NIKE, Inc. As well. Asana, Inc.'s price target was cut from $18 to $16. JP Morgan raised Dollar General Corporation's price target to $158.
Benzinga · 03/12 13:17
Vaxcyte Is Maintained at Buy by Mizuho
Dow Jones · 03/12 11:56
Mizuho Maintains Buy on Vaxcyte, Raises Price Target to $113
Benzinga · 03/12 11:46
Weekly Report: what happened at PCVX last week (0304-0308)?
Weekly Report · 03/11 09:21
Vaxcyte Completes Enrollment Of Phase 2 Study Evaluating VAX-24 For Prevention Of Invasive Pneumococcal Disease In Infants
Company expects to announce topline safety, tolerability and immunogenicity data by 2025. VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine. The vaccine is designed to cover more serotypes than any other in the U.S.
Benzinga · 03/04 13:34
Press Release: Vaxcyte Completes Enrollment of -2-
This press release contains forward-looking statements. These statements include statements related to the potential benefits of VAX-24 andVAX-31. Vaxcyte's actual results and timing of events could differ from those anticipated in such statements. Risks and uncertainties include the risks and uncertainties related to its vaccine candidates.
Dow Jones · 03/04 13:30
Press Release: Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants. Company Expects to Announce Topline Safety, Tolerability and Immunogenicity Data from Primary Immunization Series by the End of the First Quarter of 2025. VAX -24 is designed to prevent invasive pneumococcal disease in healthy infants. The study is evaluating the safety, tolerability and immunogenicity of a 24-Valent Pneumocococcal Conjugate Vaccine. VAx-24 designed to cover more serotypes than any infant vaccine on-market or in U.
Dow Jones · 03/04 13:30
Weekly Report: what happened at PCVX last week (0226-0301)?
Weekly Report · 03/04 09:21
Vaxcyte, Inc.: Report of proposed sale of securities
Press release · 03/01 23:07
Analysts Are Bullish on Top Healthcare Stocks: AdaptHealth (AHCO), LAVA Therapeutics (LVTX)
TipRanks · 03/01 06:23
More
Webull provides a variety of real-time PCVX stock news. You can receive the latest news about Vaxcyte, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About PCVX
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.